Sentinel Oncology add ADME From O2h to Their New Extended Contract

CAMBRIDGE, England, October 25, 2010 - Executives from Sentinel Oncology Limited (Cambridge,UK)
signed an agreement with O2h (Ahmedabad, India) to extend the number of FTEs
working for Sentinel Oncology. Under this new contract, O2h will also provide
ADME services to Sentinel Oncology.

Bob Boyle, CEO of Sentinel Oncology said that he appreciated
O2h's continual support and it being a reliable chemistry partner, providing
flexible multi-FTE chemistry support to the company.

COO of Sentinel Oncology, Stuart Travers said "ADME support
added onto the chemistry FTEs provides us with a seamless and quick way of
gathering data for our on-going projects. We look forward to working with O2h
and of taking advantage of its expanding ADME portfolio."

Sunil Shah, CEO, O2h "We have an incredibly good relationship
with Sentinel Oncology and are happy to continue supporting their virtual
model with not just our chemistry but also ADME. O2h ADME services are being
expanded with current purchase of high-spec specialised instruments and
support of our long-standing clients is appreciated."

About Oxygen Healthcare Ltd

O2h is a 5 year old discovery services company co-located in
Cambridge, UK and Ahmedabad, India. The Indian operations provide a high
level of chemistry expertise while UK office provides project management
support. Current clients of O2h include several top 20 pharmaceutical and
biotechnology companies in the US, Europe and Japan. O2h adheres to the
highest standards of performance with a particular emphasis on rapid
interactive communications and delivery speed. Services provided by O2h
include FTE-based synthetic chemistry, medicinal chemistry, computational
chemistry, full services lab-units and ADME. Further information on O2h can
be found at www.o2h.com.

About Sentinel Oncology Limited

Sentinel Oncology was founded at the beginning of 2005 and has
built a pipeline of small molecules designed to target the hallmarks of solid
tumours. In particular, Sentinel Oncology is developing small molecule
inhibitors that are activated selectively under tumour Hypoxia (the low
oxygen environment found in many solid tumours). Our vision is to develop new
drugs for the treatment of cancer that are void of the systemic toxicities
often associated with current therapies. Further information on Sentinel
Onology can be found at www.sentineloncology.com/.

Ekta Ahuja, +44-1223-437014